D. E. Shaw & Co. Inc. Has $3.91 Million Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)

D. E. Shaw & Co. Inc. lifted its position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 18.8% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 720,105 shares of the biopharmaceutical company's stock after buying an additional 114,173 shares during the quarter. D. E. Shaw & Co. Inc. owned about 1.18% of Sage Therapeutics worth $3,910,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Thrivent Financial for Lutherans increased its position in shares of Sage Therapeutics by 108.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 74,625 shares of the biopharmaceutical company's stock worth $405,000 after purchasing an additional 38,876 shares during the period. Jane Street Group LLC increased its position in shares of Sage Therapeutics by 103.1% in the fourth quarter. Jane Street Group LLC now owns 462,004 shares of the biopharmaceutical company's stock worth $2,509,000 after purchasing an additional 234,528 shares during the period. Amundi bought a new position in shares of Sage Therapeutics in the fourth quarter worth $166,000. SG Americas Securities LLC increased its position in shares of Sage Therapeutics by 57.7% in the fourth quarter. SG Americas Securities LLC now owns 22,498 shares of the biopharmaceutical company's stock worth $122,000 after purchasing an additional 8,228 shares during the period. Finally, Empowered Funds LLC bought a new position in shares of Sage Therapeutics in the fourth quarter worth $91,000. Institutional investors and hedge funds own 99.22% of the company's stock.

Sage Therapeutics Price Performance

Shares of Sage Therapeutics stock traded down $0.08 during midday trading on Friday, reaching $6.53. The company had a trading volume of 770,577 shares, compared to its average volume of 1,196,563. The stock has a fifty day moving average price of $7.32 and a 200 day moving average price of $6.74. The firm has a market cap of $408.92 million, a PE ratio of -0.99 and a beta of 0.20. Sage Therapeutics, Inc. has a fifty-two week low of $4.62 and a fifty-two week high of $13.47.

Sage Therapeutics (NASDAQ:SAGE - Get Free Report) last posted its quarterly earnings data on Tuesday, April 29th. The biopharmaceutical company reported ($1.01) EPS for the quarter, missing analysts' consensus estimates of ($0.99) by ($0.02). Sage Therapeutics had a negative return on equity of 68.18% and a negative net margin of 971.50%. The company had revenue of $14.06 million during the quarter, compared to analyst estimates of $14.12 million. During the same period in the prior year, the firm earned ($1.80) earnings per share. Sage Therapeutics's revenue was up 78.0% compared to the same quarter last year. As a group, sell-side analysts forecast that Sage Therapeutics, Inc. will post -3.52 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on SAGE shares. Canaccord Genuity Group decreased their price target on Sage Therapeutics from $9.00 to $8.00 and set a "hold" rating on the stock in a research report on Wednesday, February 12th. Bank of America assumed coverage on Sage Therapeutics in a research report on Tuesday, March 11th. They issued an "underperform" rating and a $5.00 target price on the stock. Wedbush reiterated a "neutral" rating and issued a $6.00 target price on shares of Sage Therapeutics in a research report on Wednesday, February 12th. Wall Street Zen cut Sage Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday, May 19th. Finally, Needham & Company LLC reiterated a "hold" rating on shares of Sage Therapeutics in a research report on Friday, April 25th. Three equities research analysts have rated the stock with a sell rating, fifteen have given a hold rating and two have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Sage Therapeutics currently has a consensus rating of "Hold" and an average target price of $8.81.

Sage Therapeutics Profile

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.